Physician profile
Sunay Shah
NPI 1578877304
$2,448.15
in general payments reported to CMS, 2019-2025
27 companies · $1,164 in 2025
The $1,164 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.83 · 2020: $19.47 · 2021: $14.02 · 2023: $270 · 2024: $903 · 2025: $1,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,337.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $357.52 | 2024-2025 | |
| Medtronic, INC. | $200.70 | 2023 | Harmony |
| Merck Sharp & Dohme LLC | $199.29 | 2024-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $169.72 | 2024-2025 | |
| Amgen INC. | $165.96 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $138.14 | 2024 | Mitraclip |
| Inspire Medical Systems, INC. | $132.40 | 2025 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $131.49 | 2023-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $120.69 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Cvrx, INC. | $109.16 | 2024-2025 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $97.98 | 2025 | |
| Shockwave Medical, INC | $89.58 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Chiesi USA, INC. | $77.99 | 2024-2025 | Juxtapid |
| Janssen Pharmaceuticals, INC | $66.90 | 2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $60.46 | 2024-2025 | Opsumit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $58.52 | 2024-2025 | Impella |
| Edwards Lifesciences Corporation | $55.95 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Lilly USA, LLC | $41.35 | 2025 | Mounjaro, Zepbound |
| Cardiva Medical, INC. | $34.15 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $27.18 | 2024 | Arcalyst |
| Celgene Corporation | $22.25 | 2024 | Camzyos |
| Csl Behring | $19.47 | 2020 | |
| Angiodynamics, INC. | $15.68 | 2019 | |
| Scpharmaceuticals INC. | $14.69 | 2023 | |
| Asahi Intecc USA, INC. | $14.02 | 2021 | |
| Vivaquant INC, Dba Rhythm Express | $13.82 | 2025 | Rhythm Express |
| Convatec INC. | $13.09 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunay Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.